vs

Side-by-side financial comparison of PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) and Repay Holdings Corp (RPAY). Click either name above to swap in a different company.

Repay Holdings Corp is the larger business by last-quarter revenue ($78.6M vs $44.6M, roughly 1.8× PACIFIC BIOSCIENCES OF CALIFORNIA, INC.). PACIFIC BIOSCIENCES OF CALIFORNIA, INC. runs the higher net margin — -90.4% vs -178.3%, a 87.9% gap on every dollar of revenue. On growth, PACIFIC BIOSCIENCES OF CALIFORNIA, INC. posted the faster year-over-year revenue change (13.8% vs 0.4%). Repay Holdings Corp produced more free cash flow last quarter ($23.2M vs $-19.9M). Over the past eight quarters, PACIFIC BIOSCIENCES OF CALIFORNIA, INC.'s revenue compounded faster (7.3% CAGR vs -1.3%).

Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides and sequencing by binding (SBB) chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension.

Repay Holdings Corp is a leading payment technology provider delivering integrated end-to-end payment processing solutions for businesses across North America. Its offerings include credit/debit card processing, ACH transfer services, POS system integrations and digital payment tools, serving retail, healthcare, automotive and e-commerce segments to help clients streamline transaction workflows and boost operational efficiency.

PACB vs RPAY — Head-to-Head

Bigger by revenue
RPAY
RPAY
1.8× larger
RPAY
$78.6M
$44.6M
PACB
Growing faster (revenue YoY)
PACB
PACB
+13.4% gap
PACB
13.8%
0.4%
RPAY
Higher net margin
PACB
PACB
87.9% more per $
PACB
-90.4%
-178.3%
RPAY
More free cash flow
RPAY
RPAY
$43.2M more FCF
RPAY
$23.2M
$-19.9M
PACB
Faster 2-yr revenue CAGR
PACB
PACB
Annualised
PACB
7.3%
-1.3%
RPAY

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
PACB
PACB
RPAY
RPAY
Revenue
$44.6M
$78.6M
Net Profit
$-40.4M
$-140.1M
Gross Margin
37.1%
74.2%
Operating Margin
-92.3%
-182.2%
Net Margin
-90.4%
-178.3%
Revenue YoY
13.8%
0.4%
Net Profit YoY
-1802.7%
-3304.1%
EPS (diluted)
$-0.11
$-1.68

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PACB
PACB
RPAY
RPAY
Q4 25
$44.6M
$78.6M
Q3 25
$38.4M
$77.7M
Q2 25
$39.8M
$75.6M
Q1 25
$37.2M
$77.3M
Q4 24
$39.2M
$78.3M
Q3 24
$40.0M
$79.1M
Q2 24
$36.0M
$74.9M
Q1 24
$38.8M
$80.7M
Net Profit
PACB
PACB
RPAY
RPAY
Q4 25
$-40.4M
$-140.1M
Q3 25
$-38.0M
$-6.4M
Q2 25
$-41.9M
$-102.3M
Q1 25
$-426.1M
$-7.9M
Q4 24
$2.4M
$-4.1M
Q3 24
$-60.7M
$3.2M
Q2 24
$-173.3M
$-4.1M
Q1 24
$-78.2M
$-5.2M
Gross Margin
PACB
PACB
RPAY
RPAY
Q4 25
37.1%
74.2%
Q3 25
41.4%
74.4%
Q2 25
36.9%
75.7%
Q1 25
-3.7%
75.9%
Q4 24
25.6%
76.3%
Q3 24
25.0%
77.8%
Q2 24
16.5%
78.2%
Q1 24
29.1%
76.2%
Operating Margin
PACB
PACB
RPAY
RPAY
Q4 25
-92.3%
-182.2%
Q3 25
-101.1%
-3.9%
Q2 25
-112.8%
-138.7%
Q1 25
-1154.5%
-4.7%
Q4 24
-390.1%
-1.5%
Q3 24
-160.3%
-0.9%
Q2 24
-488.3%
-4.6%
Q1 24
-209.6%
-3.1%
Net Margin
PACB
PACB
RPAY
RPAY
Q4 25
-90.4%
-178.3%
Q3 25
-98.9%
-8.3%
Q2 25
-105.4%
-135.2%
Q1 25
-1146.8%
-10.3%
Q4 24
6.0%
-5.3%
Q3 24
-151.9%
4.1%
Q2 24
-481.3%
-5.4%
Q1 24
-201.4%
-6.5%
EPS (diluted)
PACB
PACB
RPAY
RPAY
Q4 25
$-0.11
$-1.68
Q3 25
$-0.13
$-0.08
Q2 25
$-0.14
$-1.15
Q1 25
$-1.44
$-0.09
Q4 24
$-0.44
$-0.04
Q3 24
$-0.22
$0.03
Q2 24
$-0.64
$-0.04
Q1 24
$-0.29
$-0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PACB
PACB
RPAY
RPAY
Cash + ST InvestmentsLiquidity on hand
$279.5M
$115.7M
Total DebtLower is stronger
$280.1M
Stockholders' EquityBook value
$5.3M
$484.4M
Total Assets
$784.1M
$1.2B
Debt / EquityLower = less leverage
0.58×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PACB
PACB
RPAY
RPAY
Q4 25
$279.5M
$115.7M
Q3 25
$298.7M
$95.7M
Q2 25
$314.7M
$162.6M
Q1 25
$343.1M
$165.5M
Q4 24
$389.9M
$189.5M
Q3 24
$471.1M
$168.7M
Q2 24
$509.8M
$147.1M
Q1 24
$561.9M
$128.3M
Total Debt
PACB
PACB
RPAY
RPAY
Q4 25
$280.1M
Q3 25
$279.5M
Q2 25
$279.0M
Q1 25
$497.6M
Q4 24
$496.8M
Q3 24
$496.2M
Q2 24
$435.6M
Q1 24
$434.9M
Stockholders' Equity
PACB
PACB
RPAY
RPAY
Q4 25
$5.3M
$484.4M
Q3 25
$36.1M
$616.9M
Q2 25
$61.5M
$633.7M
Q1 25
$91.6M
$755.7M
Q4 24
$506.6M
$761.3M
Q3 24
$453.1M
$754.7M
Q2 24
$492.7M
$815.4M
Q1 24
$649.0M
$813.8M
Total Assets
PACB
PACB
RPAY
RPAY
Q4 25
$784.1M
$1.2B
Q3 25
$803.2M
$1.3B
Q2 25
$825.5M
$1.4B
Q1 25
$860.8M
$1.5B
Q4 24
$1.3B
$1.6B
Q3 24
$1.5B
$1.6B
Q2 24
$1.5B
$1.5B
Q1 24
$1.7B
$1.5B
Debt / Equity
PACB
PACB
RPAY
RPAY
Q4 25
0.58×
Q3 25
0.45×
Q2 25
0.44×
Q1 25
0.66×
Q4 24
0.65×
Q3 24
0.66×
Q2 24
0.53×
Q1 24
0.53×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PACB
PACB
RPAY
RPAY
Operating Cash FlowLast quarter
$-19.1M
$23.3M
Free Cash FlowOCF − Capex
$-19.9M
$23.2M
FCF MarginFCF / Revenue
-44.6%
29.6%
Capex IntensityCapex / Revenue
1.9%
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-114.1M
$90.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PACB
PACB
RPAY
RPAY
Q4 25
$-19.1M
$23.3M
Q3 25
$-18.7M
$32.2M
Q2 25
$-29.4M
$33.1M
Q1 25
$-44.1M
$2.5M
Q4 24
$-30.6M
$34.3M
Q3 24
$-45.5M
$60.1M
Q2 24
$-54.3M
$31.0M
Q1 24
$-75.7M
$24.8M
Free Cash Flow
PACB
PACB
RPAY
RPAY
Q4 25
$-19.9M
$23.2M
Q3 25
$-18.8M
$32.1M
Q2 25
$-29.9M
$33.0M
Q1 25
$-45.4M
$2.4M
Q4 24
$-32.3M
$34.0M
Q3 24
$-46.3M
$59.8M
Q2 24
$-55.7M
$30.5M
Q1 24
$-79.6M
$24.7M
FCF Margin
PACB
PACB
RPAY
RPAY
Q4 25
-44.6%
29.6%
Q3 25
-48.9%
41.3%
Q2 25
-75.3%
43.6%
Q1 25
-122.3%
3.0%
Q4 24
-82.3%
43.5%
Q3 24
-115.7%
75.6%
Q2 24
-154.8%
40.7%
Q1 24
-205.0%
30.6%
Capex Intensity
PACB
PACB
RPAY
RPAY
Q4 25
1.9%
0.1%
Q3 25
0.2%
0.2%
Q2 25
1.4%
0.1%
Q1 25
3.7%
0.2%
Q4 24
4.1%
0.3%
Q3 24
2.0%
0.3%
Q2 24
4.1%
0.6%
Q1 24
10.0%
0.1%
Cash Conversion
PACB
PACB
RPAY
RPAY
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-12.93×
Q3 24
18.52×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PACB
PACB

Products$39.0M87%
Service And Other$5.7M13%

RPAY
RPAY

Sales Channel Directly To Consumer$69.4M88%
Other$6.8M9%
Sales Channel Through Intermediary$2.3M3%

Related Comparisons